Rx Profiler – Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer


Breast Cancer

Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Introduction Based on current incidence rates, 12.4% of women born in the United States today will develop breast cancer at some time during their life.1 At the time of diagnosis, [ Read More ]

Perspectives

A Pharmacist’s Perspective on CDK4/6 Inhibitors

Robert C. Wolf, PharmD Assistant Professor, Department of Hematology & Oncology Pharmacy
Mayo Clinic, Rochester, MN 

Breast cancer is the most common cancer in women and remains a leading cause of cancer-related morbidity, mortality, and resource utilization. For patients with advanced breast cancer, prognosis remains especially [ Read More ]

Perspectives

A Payer’s Perspective on CDK4/6 Inhibitors

Kenneth L. Schaecher, MD, FACP, CPC
Associate Chief Medical Officer, University of Utah Health Plans,
Attending Physician – Internal Medicine, Granger Medical Clinic
Salt Lake City, UT 

As pointed out in this monograph, breast cancer remains a significant issue for patients and payers, as it is one of the highest-prevalence cancers and, thus, results in high costs. [ Read More ]

Perspectives

A Nurse Navigator’s Perspective on CDK4/6 Inhibitors

Sharon S. Gentry, RN, MSN, CBCN, CBEC, ONN-CG
Breast Nurse Navigator
Novant Health Derrick L. Davis Cancer Center
Winston-Salem, NC 

Metastatic breast cancer (MBC) or advanced breast cancer (ABC) signifies that cancer has spread to a distant organ site, either as a progression or a recurrence after a patient has [ Read More ]